Things
The D3 4 Health project, financed from the resources provided by the Complementary Fund to the National Recovery and Resilience Plan - Intervention 1 - Research initiatives for innovative technologies and paths in the health and care sector (DD 931), aims at the development of digital twins and biological through a data mining approach. These twins will be obtained from the collection of health data analyzed by algorithms powered by artificial intelligence on a multi-layered platform and by innovative technologies, such as wearable devices, sensors and biomarkers for the diagnosis, monitoring and therapy of five reference diseases .
Who is it aimed at?
The subjects eligible to submit project proposals, Proponents, in response to this call, even in collaborative mode, can be companies or research organizations, based in Italy, as reported below: - Micro, Small and Medium Enterprises (MSMEs) with the dimensional parameters referred to in Annex I of REG (EC) no. 800/2008 of the Commission of 6 August 2008 (General block exemption regulation) in OJEU L 214 of 9.8.2008; - Innovative startups established no more than 24 months ago (art. 25 of Legislative Decree 179/2012); - Large companies (GI); - Companies with an operational headquarters on Italian territory (i.e. which undertake to activate an office in Italy by the date of signature of the provision granting the relief); - Universities, EPR supervised by the MUR, by the public IRCCS and other bodies supervised by the Ministry of Health; - Research organizations registered in the National Research Registry. The partners of the D3 4 Health project and the entities they participate in cannot be beneficiaries of the funding provided for in this notice.
What does it predict
The general objective of Spoke 3 coordinated by Sapienza as part of the D34Health project is the development and validation of new wearable technologies, chemical and optical breath analyses, sensors and biomarkers, to provide accessible diagnostic, monitoring and therapeutic pathways for colorectal cancer metastatic to the liver (D1), liver and biliary tract cancer (D2), central nervous system tumors (D3), type I diabetes (D4) and multiple sclerosis (D5) as reference diseases. The D3 4 Health project will transform and advance current methodologies for managing landmark diseases by facilitating the application of precision medicine approaches through new artificial intelligence algorithms, mathematical models and medical devices to benefit patients across the country national. The activities planned within Spoke 3 will be divided into three phases: 1. Development of technological solutions and identification of biomarkers; 2. Validation of technological solutions and biomarkers; 3. Construction of the digital twin.
